Clinical trial
A Phase 2 Study of SYS6002 in Combination With JMT101 and Enlonstobart Injection in Participants With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
NCT06989671 is registered in ClinicalTrials.gov with CSPC Megalith Biopharmaceutical Co.,Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of SYS6002 in Combination With JMT101 and Enlonstobart Injection in Participants With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- August 30, 2025
- Completion date
- July 30, 2028
- Enrollment
- 430 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck squamous cell carcinoma